CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 500 filers reported holding CRISPR THERAPEUTICS AG in Q2 2021. The put-call ratio across all filers is 1.18 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $714 | +2.7% | 14,514 | +17.3% | 0.00% | -33.3% |
| Q2 2023 | $695 | +24.1% | 12,372 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $560 | -24.3% | 12,372 | -32.0% | 0.00% | -25.0% |
| Q4 2022 | $740 | -99.9% | 18,207 | 0.0% | 0.00% | -42.9% |
| Q3 2022 | $1,190,000 | +183.3% | 18,207 | +163.2% | 0.01% | +250.0% |
| Q2 2022 | $420,000 | -3.2% | 6,917 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $434,000 | -17.2% | 6,917 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $524,000 | -32.3% | 6,917 | 0.0% | 0.00% | -33.3% |
| Q3 2021 | $774,000 | -30.9% | 6,917 | 0.0% | 0.00% | -40.0% |
| Q2 2021 | $1,120,000 | +32.9% | 6,917 | 0.0% | 0.01% | +25.0% |
| Q1 2021 | $843,000 | -20.4% | 6,917 | 0.0% | 0.00% | -20.0% |
| Q4 2020 | $1,059,000 | +82.9% | 6,917 | 0.0% | 0.01% | +66.7% |
| Q3 2020 | $579,000 | +14.0% | 6,917 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $508,000 | – | 6,917 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $31,294,000 | 31.24% |
| NEA Management Company, LLC | 1,590,002 | $365,593,000 | 10.56% |
| Ariose Capital Management Ltd | 37,900 | $2,379,000 | 9.30% |
| ARK Investment Management | 9,404,071 | $590,294,000 | 2.46% |
| NIA IMPACT ADVISORS, LLC | 80,082 | $5,027,000 | 2.44% |
| Nikko Asset Management Americas, Inc. | 4,619,747 | $291,044,000 | 2.14% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,139,000 | 1.98% |
| Integral Health Asset Management, LLC | 120,000 | $7,532,000 | 1.96% |
| Valiant Capital Management, L.P. | 240,683 | $15,108,000 | 1.73% |
| Deuterium Capital Management, LLC | 18,000 | $1,130,000 | 1.45% |